Skip to main content

Table 3 Changes in lab parameters and KCCQ

From: Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial

 

Vitamin D

95% CI

Placebo

95% CI

p-value

Corrected model p-value

BNP

30 ± 950

−10, 70

400 ± 1900

210–600

0.002*

0.003*

PTH

−20 ± 20

−28, −11

7 ± 53

16, 30

<0.002*

0.07

hsCRP

−1 ± 5

−3, 1

1 ± 6

−2, 4

0.18

0.21

25-(OH)D

51 ± 32

39,62

1 ± 6

−2, 3

<0.001*

Na

Physical Score

9 ± 14

3,15

−5 ± 20

−4, 14

0.02*

0.07

Symptom Frequency

10 ± 28

−2, 28

−6 ± 17

−2, 13

0.03*

0.06

Symptom Burden

12 ± 20

3, 20

−7 ± 15

−14, 0

0.002*

0.05*

Total Symptom

11 ± 22

1, 22

−6 ± 17

−13, 1

0.013*

0.03*

Stability Score

3 ± 35

−13, 18

1 ± 14

−5,7

0.88

0.84

QOL Score

11 ± 21

3, 21

−2 ± 20

−11, 7

0.05*

0.11

Social Score

10 ± 24

0, 24

−4 ± 27

−16, 8

0.14

0.27

Overall Summary Score

10 ± 15

4,17

−6 ± 15

−13, 1

<0.02*

0.01*

Clinical Summary Score

8 ± 14

2, 14

−8 ± 18

−16, 0

0.02*

0.01*

  1. Data are expressed as mean ± SD, 95% CI
  2. Abbreviations: Kansas City Cardiomyopathy Questionnaire (KCCQ), Standard Deviation (SD), Confidence Interval (CI), B-type Natriuretic Peptide (BNP), Parathyroid Hormone (PTH), high sensitivity c-reactive protein (hsCRP), 25 hydroxyvitamin D (25-(OH)D), Quality of Life Score (QOL)
  3. *Indicates significant difference between groups